Bristol-Myers Squibb Co (NYSE:BMY) Pays $13.1 Billion For MyoKardia Inc. (NASDAQ:MYOK) Heart Therapies

Bristol-Myers Squibb Co (NYSE:BMY) has reached an agreement to acquire drug maker MyoKardia Inc. (NASDAQ:MYOK) for $13.1 billion. With the acquisition, the drug giant is poised to expand its pipeline of drugs offerings into heart therapies, including lead product Mavacamten for treating obstructive hypertrophic cardiomyopathy.

Bristol Myers Acquisition

Bristol Myers also intends to use MyoKardia’s Mavacamten in clinical trials as a potential treatment for hypertrophic cardiomyopathy. The chronic condition affects the heart, resulting in wall thickening, which makes it hard for the organ to pump blood. The condition affects close to one in every 500 people. An application for regulatory approval of Mavacamten is scheduled for the first quarter of next year.

Under the terms of the deal, Bristol Myers is to pay $225 a share for MyoKardia, representing a 61% premium to Friday’s closing price. Bristol Myers is to finance the deal with a combination of cash and debt. Despite the soaring debt levels, the company insists it will continue to pursue deals large and small in a bid to strengthen its drug pipeline and competitive edge.

The acquisition comes barely a year after the company closed a $74 billion takeover of Celgene Corp. The company is also yet to complete paying down the debt it took to acquire Celgene. Its debt currently stands at more than $47 billion.

Expanding Drug Pipeline

The acquisition of MyoKardia will help Bristol Myers expand its lineup of heart drugs. The deal will also help the company maintain a more diversified lineup of therapies after affirming plans to focus on the oncology business. The acquisition could not have come at a better time as the company is staring patent expiration of crucial drugs.

Amid the acquisition spree, investors remain wary of the combined company’s long term growth prospects. There are concerns that the combined company will only have few growth prospects in the latter stages of the decade. For instance, the company’s main drug Revlimid is poised to lose patent protection in 2027. Eliquis, another drug, is posed to lose exclusivity in 2026.

By reading our website you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold us, our editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook or chat. We do not advise any reader to take any specific action. Our releases are for informational and educational purposes only. Never invest purely based on our articles. Gains mentioned on our website, twitter, Facebook, and on our website may be based on EOD or intraday data. We may be compensated for the production, release, and awareness of this article. We will disclose any and all compensation on the article page. This publication and its owner never hold positions in the securities mentioned in our articles. Our information may contain Forward-Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site. The information in our disclaimers is subject to change at any time without notice. We are not held liable or responsible for the information in press releases issued by the companies discussed in these write-ups. Please do your own due diligence